Top

Published in:

Open Access 01-07-2015 | Review Article

The Short-Term Remission of Diabetic Nephropathy After Roux-en-Y Gastric Bypass in Chinese Patients of T2DM with Obesity

Authors: Hongwei Zhang, Jianzhong Di, Haoyong Yu, Xiaodong Han, Kun Li, Pin Zhang

Published in: Obesity Surgery | Issue 7/2015

Abstract

The study aimed to examine the effect of gastric bypass on diabetic nephropathy (DN) in Chinese patients. A retrospective study of 101 samples with DN stages I to IV underwent Roux-en-Y gastric bypass. Anthropometric and biochemical parameters were assessed during a 1-year follow-up. Binary logistic regression analysis was used for predictors and ROC for cutoff points. There was significant reduction of medication for diabetes and hypertension. Overall remission of T2DM was 80.2 %. Preoperative albumin/creatinine ratio (ACR) and serum creatinine (SCr) levels could be predictors for DN remission, and the cutoff points were 126 mg/g cr and 57 μmol/L, respectively. Gastric bypass showed improvement of T2DM and DN. Gastric bypass may be more beneficial for those with lower preoperative ACR and SCr.

Available only for authorised users

National Diabetes Research Group. A mass survey of diabetes mellitus in a pospulation of 300,000 in 14 provinces and municipalities in China. Zhonghua Nei Ke Za Zhi. 1981;20(11):678–83.

Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948–59.PubMedCrossRef

Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy. Am J Kidney Dis. 2003;41:S19–21.PubMedCrossRef

Atkins RC, Zimmet P. Diabetic kidney disease: act now or pay later. Kidney Int. 2010;77:375–7.PubMedCrossRef

Lim AKH. Diabetic nephropathy—complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361–81.PubMedCentralPubMedCrossRef

International Diabetes Federation. IDF Diabetes Atlas 6thed Brussels, Belgium: International Diabetes Federation; 2013. Available from: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed September 2, 2014.2.

Lv M, Chen Z, Hu GY, et al. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discov Today. 2014;00:1–15.

Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med. 2011;28:628–42.PubMedCentralPubMedCrossRef

Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–85.PubMedCrossRef

10.

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13.PubMedCrossRef

11.

Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.PubMedCrossRef

12.

Vetter ML, Cardillo S, Rickels MR, et al. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009;150:94–103. 480.PubMedCrossRef

13.

Yu H, Di J, Bao Y, et al. Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m². Surg Obes Relat Dis. 2014.

14.

Kun L, Pin Z, Jianzhong D, et al. Significant improvement of erectile function after Roux-en-Y gastric bypass surgery in obese Chinese men with erectile dysfunction. Obes Surg. 2014. [Epub ahead of print].

15.

Zou J, Zhang P, Yu H, et al. Effect of laparoscopic Roux-en-Y gastric bypass surgery on obstructive sleep apnea in a Chinese population with obesity and T2DM. Obes Surg. 2014. [Epub ahead of print].

16.

Mogensen CE, Schmitz O. The diabetic kidney: from hyperfiltration and microalbuminuria to end-stage renal failure. Med Clin N Am. 1988;72(6):1465–92.PubMed

17.

Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes. Diabetes Care. 2009;32:2133–5.PubMedCentralPubMedCrossRef

18.

Huang CK, Lee YC, Hung CM, et al. Laparoscopic Roux-en-Y gastric bypass for morbidly obese Chinese patients: learning curve, advocacy and complications. Obes Surg. 2008;18(7):776–81.PubMedCrossRef

19.

Huang W, Gallois Y, Bouby N, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A. 2001;98(23):13330–4.PubMedCentralPubMedCrossRef

20.

Rudberg S, Rasmussen LM, Bangstad HJ, et al. Influence of insertion/ deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care. 2000;23(4):544–8.PubMedCrossRef

21.

Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care. 2002;25(5):859–64.PubMedCrossRef

22.

Kanetsuna Y, Takahashi K, Nagata M, et al. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol. 2007;170(5):1473–84.PubMedCentralPubMedCrossRef

23.

Lanaspa MA, Ishimoto T, Cicerchi C, et al. Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. J Am Soc Nephrol. 2014.

24.

Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002;288(20):2579–88.PubMedCrossRef

25.

Mooyaart AL. Genetic associations in diabetic nephropathy. Clin Exp Nephrol. 2013;54:544–53.

26.

Viberti G, Mogensen CE, Groop LC, et al. European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994;271(4):275–9.PubMedCrossRef

27.

Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16:3027–37.PubMedCrossRef

28.

Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis. 2004;44(5):792–8.PubMedCrossRef

29.

Molitch ME, DeFronzo RA, Franz MJ, et al. American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S79–83.PubMed

30.

Alexander JW, Goodman HR, Hawver LM, et al. Improvement and stabilization of chronic kidney disease after gastric bypass. Surg Obes Relat Dis. 2009;2:237–41.CrossRef

Title: The Short-Term Remission of Diabetic Nephropathy After Roux-en-Y Gastric Bypass in Chinese Patients of T2DM with Obesity
Authors: Hongwei Zhang
Jianzhong Di
Haoyong Yu
Xiaodong Han
Kun Li
Pin Zhang
Publication date: 01-07-2015
Publisher: Springer US
Published in: Obesity Surgery / Issue 7/2015
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-015-1666-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Short-Term Remission of Diabetic Nephropathy After Roux-en-Y Gastric Bypass in Chinese Patients of T2DM with Obesity

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2015

Patterns of Weight Loss Response Following Gastric Bypass and Sleeve Gastrectomy

A Simple Trick to Prevent VOMIT After Sleeve Gastrectomy

Response to the Comment on “Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model”

Clinical Benefit of Gastric Staple Line Reinforcement (SLR) in Gastrointestinal Surgery: a Meta-analysis

Examination of the Beck Depression Inventory-II Factor Structure Among Bariatric Surgery Candidates

Risk Factors for Postoperative Morbidity After Totally Robotic Gastric Bypass in 302 Consecutive Patients